Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective method to cure non-malignant hematological diseases. Umbilical cord blood stem cells (UCB) are characterized by weak immunogenicity, good tolerance human leukocyte antigen (HLA) mismatch, low incidence of graft-versus-host disease and relatively fast availability. UCB can be used as the graft of allo-HSCT for patients with non-malignant hematological diseases. This article reviews the efficacy of the umbilical cord blood stem cell transplantation (UCBT) in patients with primary immunodeficiency, hereditary bone marrow failure, hereditary metabolic diseases and autoimmune diseases. Key words: Umbilical cord blood; Stem cells; Transplantation; Non-malignant diseases

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.